Recursion Pharmaceuticals has secured $239 million in new venture capital financing, plus a long-term collaboration deal with Bayer to help boost its pipeline in fibrotic diseases of the lung, heart, ...
26d
Recursion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Delivered first clinical validation of the Recursion full stack AI Operating System in FAP, demonstrating translation from AI ...
Digital drug-discovery startup Recursion Pharmaceuticals Inc. has formed a partnership with Bayer AG that could be worth more than $1 billion and also raised a $239 million venture financing round led ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results